Report cover image

Global Dementia Treatment Market Size Study, By Indication (Alzheimer’s Disease Dementia, Vascular Dementia, Lewy Body Dementia, Frontotemporal Dementia, Parkinson Disease Dementia, Others), By Drug Class (Cholinesterase Inhibitors, NMDA Receptor Antagoni

Publisher Factview Research
Published Oct 03, 2025
Length 285 Pages
SKU # FAVR20464113

Description

The Global Dementia Treatment Market is poised for substantial growth, estimated at USD 18.03 billion in 2024 and projected to expand at a compound annual growth rate CAGR of 8.4% over the forecast period 2025-2034. The rapid expansion is largely driven by high disease prevalence, an aging global population, and increasing research and development (R&D) initiatives focused on novel therapeutic solutions. As the burden of dementia continues to rise, governments and healthcare organizations worldwide are ramping up efforts to enhance diagnosis, treatment accessibility, and patient awareness programs.

In 2024, over 55 million people worldwide were diagnosed with dementia, with projections indicating an increase to 78 million by 2030 and 139 million by 2050, according to the World Health Organization (WHO). The introduction of innovative pharmaceutical therapies and government-backed funding for clinical research have further bolstered market expansion. For instance, in July 2024, the U.S. Food and Drug Administration (FDA) granted approval for Leqembi (lecanemab), an Alzheimer’s treatment developed by Eisai Co., Ltd., to help slow cognitive decline. Similarly, government initiatives such as the U.S. Department of Health & Human Services' (HHS) roadmap for dementia care, unveiled in December 2024, emphasize research support and treatment accessibility.

The development of next-generation therapies, such as anti-amyloid antibodies, is emerging as a transformative trend within the dementia treatment market. Lecanemab and donanemab, two promising drug candidates, have demonstrated 27% and 35% reductions in cognitive decline, respectively, after 18 months of treatment. Furthermore, a robust pipeline of phase 1, phase 2, and phase 3 clinical trials continues to drive optimism among pharmaceutical developers and investors.

From a regional perspective, North America dominated the global market in 2024, accounting for 37.6% of the total revenue. This dominance is attributed to a high disease burden, strong presence of key market players, and well-established healthcare infrastructure. Europe follows closely, with countries like Germany, France, and the UK investing heavily in dementia research. Meanwhile, the Asia-Pacific region is anticipated to witness the fastest CAGR of 9.5% , fueled by expanding healthcare facilities, increasing awareness programs, and a growing elderly population.

Major Market Players Included in This Report:
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Novartis AG
  • Daiichi Sankyo Company, Limited
  • AbbVie Inc.
  • Lundbeck
  • Biogen
  • Cipla
  • Sun Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Amneal Pharmaceuticals LLC
  • Cognition Therapeutics, Inc.
  • Corium, Inc.
  • Alpha Cognition Inc.
The Detailed Segments and Sub-Segment of the Market Are Explained Below:

By Indication
  • Alzheimer’s Disease Dementia
  • Vascular Dementia
  • Lewy Body Dementia
  • Frontotemporal Dementia (FTD)
  • Parkinson Disease Dementia
  • Others
By Drug Class
  • Cholinesterase Inhibitors
  • NMDA Receptor Antagonists
  • MAO Inhibitors
  • Combination Drug
  • Others
By Route of Administration
  • Oral
  • Transdermal Patch
  • Injectable
By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
By Region

North America
  • U.S.
  • Canada
Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • Rest of Europe
Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Rest of Asia Pacific
Latin America
  • Brazil
  • Mexico
Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa
Years Considered for the Study:
  • Historical Year – 2022
  • Base Year – 2024
  • Forecast Period – 2024 to 2034
Key Takeaways:
  • Market Estimates & Forecast for 10 years (2022-2034)
  • Annualized Revenue and Regional-Level Analysis for each market segment
  • Geographical Breakdown with country-level market evaluations
  • Competitive Landscape Analysis with information on major market players
  • Insights into Key Business Strategies and recommendations for market entry and growth
  • Supply & Demand Side Analysis of the market

Table of Contents

285 Pages
Chapter 1. Global Dementia Treatment Market Executive Summary
1.1. Global Dementia Treatment Market Size & Forecast (2024-2034)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Indication
1.3.2. By Drug Class
1.3.3. By Route of Administration
1.3.4. By Distribution Channel
1.4. Key Trends
1.5. Recession Impact
1.6 Industry Metrics
1.7 Investment Analysis
1.8 Investment Rationale
1.9. Analyst Recommendation & Conclusion
Chapter 2. Global Dementia Treatment Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Dementia Treatment Market Dynamics
3.1. Market Drivers
3.1.1. Rising Geriatric Population
3.1.2. Increasing Prevalence of Dementia
3.1.3. Advancements in Drug Discovery & Approvals
3.2. Market Challenges
3.2.1. High Costs of Dementia Medications
3.2.2. Complexity in Clinical Trials & Drug Development
3.3. Market Opportunities
3.3.1. Government Initiatives & Funding
3.3.2. Expansion of Telemedicine & Online Pharmacies
Chapter 4. Global Dementia Treatment Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Dementia Treatment Market Size & Forecasts by Indication (2024-2034)
5.1. Segment Dashboard
5.2. Global Dementia Treatment Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. Alzheimer’s Disease Dementia
5.2.2. Vascular Dementia
5.2.3. Lewy Body Dementia
5.2.4. Frontotemporal Dementia
5.2.5. Parkinson Disease Dementia
5.2.6. Others
Chapter 6. Global Dementia Treatment Market Size & Forecasts by Drug Class (2024-2034)
6.1. Segment Dashboard
6.2. Global Dementia Treatment Market: Drug Class Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Cholinesterase Inhibitors
6.2.2. NMDA Receptor Antagonists
6.2.3. MAO Inhibitors
6.2.4. Combination Drug
6.2.5. Others
Chapter 7. Global Dementia Treatment Market Size & Forecasts by Route of Administration (2024-2034)
7.1. Segment Dashboard
7.2. Global Dementia Treatment Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)
7.2.1. Oral
7.2.2. Transdermal Patch
7.2.3. Injectable
Chapter 8. Global Dementia Treatment Market Size & Forecasts by Distribution Channel (2024-2034)
8.1. Segment Dashboard
8.2. Global Dementia Treatment Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
8.2.1. Hospital Pharmacy
8.2.2. Retail Pharmacy
8.2.3. Online Pharmacy
Chapter 9. Global Dementia Treatment Market Size & Forecasts by Region (2024-2034)
9.1. North America Dementia Treatment Market
9.1.1. U.S. Dementia Treatment Market
9.1.2. Canada Dementia Treatment Market
9.2. Europe Dementia Treatment Market
9.2.1. U.K. Dementia Treatment Market
9.2.2. Germany Dementia Treatment Market
9.2.3. France Dementia Treatment Market
9.2.4. Spain Dementia Treatment Market
9.2.5. Italy Dementia Treatment Market
9.2.6. Rest of Europe Dementia Treatment Market
9.3. Asia-Pacific Dementia Treatment Market
9.3.1. China Dementia Treatment Market
9.3.2. India Dementia Treatment Market
9.3.3. Japan Dementia Treatment Market
9.3.4. Australia Dementia Treatment Market
9.3.5. South Korea Dementia Treatment Market
9.3.6. Rest of Asia Pacific Dementia Treatment Market
9.4. Latin America Dementia Treatment Market
9.4.1. Brazil Dementia Treatment Market
9.4.2. Mexico Dementia Treatment Market
9.4.3. Rest of Latin America Dementia Treatment Market
9.5. Middle East & Africa Dementia Treatment Market
9.5.1. Saudi Arabia Dementia Treatment Market
9.5.2. South Africa Dementia Treatment Market
9.5.3. Rest of Middle East & Africa Dementia Treatment Market
Chapter 10. Competitive Intelligence
10.1. Key Company SWOT Analysis
10.1.1. Eisai Co., Ltd.
10.1.2. Eli Lilly and Company
10.1.3. Biogen
10.2. Top Market Strategies
10.3. Company Profiles
Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us